Limits...
Chitosan Coated Textiles May Improve Atopic Dermatitis Severity by Modulating Skin Staphylococcal Profile: A Randomized Controlled Trial.

Lopes C, Soares J, Tavaria F, Duarte A, Correia O, Sokhatska O, Severo M, Silva D, Pintado M, Delgado L, Moreira A - PLoS ONE (2015)

Bottom Line: Comparisons were made using analysis of variance supplemented by repeated measures analysis for the primary outcome.Chitosan group improved SCORAD from baseline in 43.8%, (95%CI: 30.9 to 55.9), P = 0.01, placebo group in 16.5% (-21.6 to 54.6); P = 0.02 with no significant differences between groups; Dermatology Quality of life Index Score significantly improved in chitosan group (P = 0.02) and a significant increase of skin Coagulase negative Staphylococci (P = 0.02) was seen.Moreover, a potential effect in quality of life may be considered.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Immunology, Basic and Clinical Immunology Unit, Faculty of Medicine, University of Porto, Porto, Portugal.

ABSTRACT

Background: Atopic dermatitis (AD) patients may benefit from using textiles coated with skin microbiome-modulating compounds. Chitosan, a natural biopolymer with immunomodulatory and antimicrobial properties, has been considered potentially useful.

Objective: This randomized controlled trial assessed the clinical utility of chitosan-coated garment use in AD.

Methods: Of the 102 patients screened, 78 adult and adolescents were randomly allocated to overnight use of chitosan-coated or uncoated cotton long-sleeved pyjama tops and pants for 8 weeks. The primary outcome was change in disease severity assessed by Scoring Atopic dermatitis index (SCORAD). Other outcomes were changes in quality of life, pruritus and sleep loss, days with need for rescue medication, number of flares and controlled weeks, and adverse events. Changes in total staphylococci and Staphylococcus aureus skin counts were also assessed. Comparisons were made using analysis of variance supplemented by repeated measures analysis for the primary outcome. Interaction term between time and intervention was used to compare time trends between groups.

Results: Chitosan group improved SCORAD from baseline in 43.8%, (95%CI: 30.9 to 55.9), P = 0.01, placebo group in 16.5% (-21.6 to 54.6); P = 0.02 with no significant differences between groups; Dermatology Quality of life Index Score significantly improved in chitosan group (P = 0.02) and a significant increase of skin Coagulase negative Staphylococci (P = 0.02) was seen.

Conclusions: Chitosan coated textiles may impact on disease severity by modulating skin staphylococcal profile. Moreover, a potential effect in quality of life may be considered.

Trial registration: ClinicalTrials.gov NCT01597817.

Show MeSH

Related in: MedlinePlus

Mean (95% CI) weekly pruritus and sleep loss scores in chitosan and placebo groups throughout the intervention period.CI-confidence interval.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664262&req=5

pone.0142844.g003: Mean (95% CI) weekly pruritus and sleep loss scores in chitosan and placebo groups throughout the intervention period.CI-confidence interval.

Mentions: The improvement in DLQI scores from baseline was 36% (95% CI: 23.5 to 48.1) in the chitosan group (8.0 [9.3–6.7] to 4.8 [6.2–3.4], P = 0.02) and 25% (95% CI: 6.0–44.1) in the placebo group (8.3 [10.4–6.3] to 5.6 [7.7–3.5], P = 0.28) (Fig 2). There were no significant differences between both groups. The proportion of individuals with a clinically meaningful improvement in SCORAD was 25 (67%) in the chitosan group and 20 (63%) in the placebo group. No significant effect was observed either on daily pruritus or sleep loss scores (Fig 3 and S2 Table), need for rescue medication, or number of flares or totally controlled weeks and well controlled weeks (Table 2).


Chitosan Coated Textiles May Improve Atopic Dermatitis Severity by Modulating Skin Staphylococcal Profile: A Randomized Controlled Trial.

Lopes C, Soares J, Tavaria F, Duarte A, Correia O, Sokhatska O, Severo M, Silva D, Pintado M, Delgado L, Moreira A - PLoS ONE (2015)

Mean (95% CI) weekly pruritus and sleep loss scores in chitosan and placebo groups throughout the intervention period.CI-confidence interval.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664262&req=5

pone.0142844.g003: Mean (95% CI) weekly pruritus and sleep loss scores in chitosan and placebo groups throughout the intervention period.CI-confidence interval.
Mentions: The improvement in DLQI scores from baseline was 36% (95% CI: 23.5 to 48.1) in the chitosan group (8.0 [9.3–6.7] to 4.8 [6.2–3.4], P = 0.02) and 25% (95% CI: 6.0–44.1) in the placebo group (8.3 [10.4–6.3] to 5.6 [7.7–3.5], P = 0.28) (Fig 2). There were no significant differences between both groups. The proportion of individuals with a clinically meaningful improvement in SCORAD was 25 (67%) in the chitosan group and 20 (63%) in the placebo group. No significant effect was observed either on daily pruritus or sleep loss scores (Fig 3 and S2 Table), need for rescue medication, or number of flares or totally controlled weeks and well controlled weeks (Table 2).

Bottom Line: Comparisons were made using analysis of variance supplemented by repeated measures analysis for the primary outcome.Chitosan group improved SCORAD from baseline in 43.8%, (95%CI: 30.9 to 55.9), P = 0.01, placebo group in 16.5% (-21.6 to 54.6); P = 0.02 with no significant differences between groups; Dermatology Quality of life Index Score significantly improved in chitosan group (P = 0.02) and a significant increase of skin Coagulase negative Staphylococci (P = 0.02) was seen.Moreover, a potential effect in quality of life may be considered.

View Article: PubMed Central - PubMed

Affiliation: Laboratory of Immunology, Basic and Clinical Immunology Unit, Faculty of Medicine, University of Porto, Porto, Portugal.

ABSTRACT

Background: Atopic dermatitis (AD) patients may benefit from using textiles coated with skin microbiome-modulating compounds. Chitosan, a natural biopolymer with immunomodulatory and antimicrobial properties, has been considered potentially useful.

Objective: This randomized controlled trial assessed the clinical utility of chitosan-coated garment use in AD.

Methods: Of the 102 patients screened, 78 adult and adolescents were randomly allocated to overnight use of chitosan-coated or uncoated cotton long-sleeved pyjama tops and pants for 8 weeks. The primary outcome was change in disease severity assessed by Scoring Atopic dermatitis index (SCORAD). Other outcomes were changes in quality of life, pruritus and sleep loss, days with need for rescue medication, number of flares and controlled weeks, and adverse events. Changes in total staphylococci and Staphylococcus aureus skin counts were also assessed. Comparisons were made using analysis of variance supplemented by repeated measures analysis for the primary outcome. Interaction term between time and intervention was used to compare time trends between groups.

Results: Chitosan group improved SCORAD from baseline in 43.8%, (95%CI: 30.9 to 55.9), P = 0.01, placebo group in 16.5% (-21.6 to 54.6); P = 0.02 with no significant differences between groups; Dermatology Quality of life Index Score significantly improved in chitosan group (P = 0.02) and a significant increase of skin Coagulase negative Staphylococci (P = 0.02) was seen.

Conclusions: Chitosan coated textiles may impact on disease severity by modulating skin staphylococcal profile. Moreover, a potential effect in quality of life may be considered.

Trial registration: ClinicalTrials.gov NCT01597817.

Show MeSH
Related in: MedlinePlus